+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gemcitabine Hydrochloride Market - Global Forecast 2026-2032- Product Image
Gemcitabine Hydrochloride Market - Global Forecast 2026-2032- Product Image
Sale

Gemcitabine Hydrochloride Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6282116
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Gemcitabine Hydrochloride: Clinical Role and Market Context

Gemcitabine hydrochloride is a nucleoside analogue used in oncology. Regulatory labeling and clinical guidelines identify it for several cancers, including pancreatic, non-small-cell lung, breast, ovarian, and bladder cancers, commonly in combination regimens. Its clinical value is shaped by disease incidence, treatment-line positioning, combination evidence, tolerability, supply reliability, and access to infusion-based oncology care.

Treatment Evolution Is Reshaping Gemcitabine Use

The treatment landscape is shifting from conventional cytotoxic therapy alone toward biomarker-informed, sequential, and combination-based care. Gemcitabine remains relevant where guidelines support its use, while immunotherapies, targeted agents, antibody-drug conjugates, radiation, and surgery influence how clinicians select and sequence therapy. Biosimilar and generic availability can support access, but procurement decisions also depend on manufacturing quality, shortage risk, formulation, and dependable cold-chain and injectable-drug handling.

Artificial Intelligence Is Improving Selection, Operations, and Evidence Generation

Artificial intelligence is being applied to pathology, imaging, clinical-trial recruitment, adverse-event detection, and treatment-response prediction. In gemcitabine-containing regimens, these tools may help identify patients suitable for combination therapy, anticipate toxicity, and optimize supportive care, but clinical utility depends on representative datasets, external validation, interpretability, cybersecurity, and regulatory oversight. AI can also improve demand planning and pharmacovigilance, although it does not replace clinician judgment or prospective evidence.

Regional Insights: Access Depends on Oncology Capacity and Regulation

North America generally combines advanced oncology infrastructure with stringent regulatory and reimbursement requirements. Europe emphasizes evidence-based, coordinated care, health-technology assessment, and procurement across diverse national systems. Asia-Pacific includes highly developed markets alongside rapidly expanding oncology capacity, creating variation in diagnosis, reimbursement, and injectable-drug access. Latin America faces uneven availability of specialist care and public financing. The Middle East is investing in cancer centers and precision medicine, while access differs across Gulf and non-Gulf systems. Africa continues to face substantial constraints in diagnosis, pathology, infusion capacity, essential-medicine procurement, and continuity of treatment.

Group Insights: Policy Blocs Shape Procurement and Clinical Access

ASEAN markets show varied regulatory pathways, healthcare financing, and oncology infrastructure, making regional harmonization and local partnerships important. BRICS members combine major pharmaceutical and clinical capabilities with wide internal differences in reimbursement and access. The European Union benefits from shared scientific and regulatory structures while retaining national pricing and reimbursement decisions. G7 systems tend to have mature clinical research and pharmacovigilance frameworks, but affordability and capacity pressures remain. GCC countries are strengthening centralized procurement and specialist cancer services. NATO members span diverse health systems, yet cross-border preparedness, supply resilience, and common quality expectations support attention to essential injectable medicines.

Country Insights: National Systems Determine Adoption and Continuity

Australia relies on centralized health-technology and reimbursement processes alongside specialist public and private oncology services. Brazil and Mexico face regional inequalities in cancer diagnosis and treatment access. Canada and the United States have sophisticated oncology networks, with coverage, formulary, and shortage-management policies influencing use. China and India combine expanding oncology capacity with significant geographic and affordability variation. France, Germany, Italy, Spain, and the United Kingdom operate within mature European systems, but differ in assessment, procurement, and reimbursement arrangements. Japan and South Korea have advanced clinical infrastructure and strong regulatory oversight. Russia’s access is influenced by domestic procurement, logistics, and healthcare-system conditions.

Industry Priorities: Secure Supply, Strengthen Evidence, and Expand Access

Leaders should maintain validated, diversified manufacturing and supplier networks for active ingredients, finished injectables, and critical packaging components. Evidence strategies should align gemcitabine-containing regimens with current guidelines, comparative clinical outcomes, biomarker research, and real-world safety monitoring. Access plans should account for national reimbursement, hospital procurement, dose availability, and infusion capacity. Organizations should also deploy AI selectively, with documented validation and human oversight, while supporting clinician education, shortage communication, equitable distribution, and responsible stewardship of oncology resources.

Research Methodology: Evidence-Based Assessment of Clinical and Access Drivers

This executive summary uses the market scope of gemcitabine hydrochloride and synthesizes publicly documented regulatory labeling, clinical-guideline principles, peer-reviewed oncology evidence, health-system characteristics, medicine-supply considerations, and established applications of artificial intelligence in healthcare. Regional, group, and country observations are qualitative and focus on differences in clinical practice, regulation, reimbursement, infrastructure, procurement, and patient access. No market estimates, market shares, forecasts, or company-specific claims are included.

Conclusion: Gemcitabine Remains Relevant Within an Evolving Oncology Ecosystem

Gemcitabine hydrochloride continues to occupy an established role in selected cancer treatment pathways, particularly where combination evidence and clinical guidelines support its use. Its future relevance will depend less on the drug alone than on regimen innovation, biomarker-informed care, dependable injectable supply, affordability, and the capacity of health systems to deliver treatment safely. Regional execution, disciplined evidence generation, and carefully governed AI adoption can help improve continuity and patient outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gemcitabine Hydrochloride Market, by Formulation
7.1. Introduction
7.2. Lyophilized Powder
7.3. Ready-to-Use Solution
8. Gemcitabine Hydrochloride Market, by Indication
8.1. Introduction
8.2. Pancreatic Cancer
8.3. Non-Small Cell Lung Cancer
8.4. Breast Cancer
8.5. Ovarian Cancer
8.6. Bladder Cancer
8.7. Biliary Tract Cancer
9. Gemcitabine Hydrochloride Market, by Dosage Form
9.1. Introduction
9.2. Injectable
9.3. Intravenous Infusion
10. Gemcitabine Hydrochloride Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. Gemcitabine Hydrochloride Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Gemcitabine Hydrochloride Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Gemcitabine Hydrochloride Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Accord Healthcare Ltd.
15.2. Alkem Laboratories Ltd.
15.3. Apotex Inc.
15.4. Aurobindo Pharma Limited
15.5. Bharat Serums and Vaccines Limited
15.6. Cipla Limited
15.7. Dr. Reddy’s Laboratories Ltd.
15.8. Eli Lilly and Company
15.9. Fresenius Kabi AG
15.10. Gland Pharma Limited
15.11. Glenmark Pharmaceuticals Ltd.
15.12. Hikma Pharmaceuticals PLC
15.13. Intas Pharmaceuticals Ltd.
15.14. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
15.15. Lupin Limited
15.16. Novartis AG
15.17. Pfizer Inc.
15.18. Sagent Pharmaceuticals, Inc.
15.19. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
15.20. STADA Arzneimittel AG
15.21. Sun Pharmaceutical Industries Ltd.
15.22. Teva Pharmaceutical Industries Ltd.
15.23. Viatris Inc.
15.24. Wockhardt Limited
15.25. Zydus Lifesciences Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Gemcitabine Hydrochloride Market, Years Considered for the Study
FIGURE 2. Global Gemcitabine Hydrochloride Market, Research Design
FIGURE 3. Global Gemcitabine Hydrochloride Market, Research Framework
FIGURE 4. Global Gemcitabine Hydrochloride Market, Data Triangulation
FIGURE 5. Global Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gemcitabine Hydrochloride Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 7. Global Gemcitabine Hydrochloride Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gemcitabine Hydrochloride Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Gemcitabine Hydrochloride Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gemcitabine Hydrochloride Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Gemcitabine Hydrochloride Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gemcitabine Hydrochloride Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Gemcitabine Hydrochloride Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gemcitabine Hydrochloride Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Gemcitabine Hydrochloride Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Gemcitabine Hydrochloride Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Gemcitabine Hydrochloride Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Gemcitabine Hydrochloride Market Segmentation & Coverage
TABLE 2. Global Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 4. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Ready-to-Use Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Ready-to-Use Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Ready-to-Use Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 11. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Non-Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Non-Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Non-Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Ovarian Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Ovarian Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Ovarian Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Bladder Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Bladder Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Bladder Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Biliary Tract Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Biliary Tract Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Biliary Tract Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 30. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Intravenous Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Intravenous Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Intravenous Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 37. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Gemcitabine Hydrochloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Asia-Pacific Gemcitabine Hydrochloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 52. North America Gemcitabine Hydrochloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. North America Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 54. North America Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 55. North America Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 56. North America Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 57. Latin America Gemcitabine Hydrochloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Latin America Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 59. Latin America Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 60. Latin America Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 61. Latin America Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. Europe Gemcitabine Hydrochloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Europe Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 64. Europe Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 65. Europe Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 66. Europe Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. Middle East Gemcitabine Hydrochloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Middle East Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 69. Middle East Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 70. Middle East Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 71. Middle East Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. Africa Gemcitabine Hydrochloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Africa Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 74. Africa Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 75. Africa Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 76. Africa Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Global Gemcitabine Hydrochloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. ASEAN Gemcitabine Hydrochloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. ASEAN Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 80. ASEAN Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 81. ASEAN Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 82. ASEAN Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. GCC Gemcitabine Hydrochloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. GCC Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 85. GCC Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 86. GCC Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 87. GCC Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. European Union Gemcitabine Hydrochloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. European Union Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 90. European Union Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. European Union Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 92. European Union Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. BRICS Gemcitabine Hydrochloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. BRICS Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 95. BRICS Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. BRICS Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 97. BRICS Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. G7 Gemcitabine Hydrochloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. G7 Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 100. G7 Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. G7 Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 102. G7 Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. NATO Gemcitabine Hydrochloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. NATO Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 105. NATO Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. NATO Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 107. NATO Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. Global Gemcitabine Hydrochloride Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. United States Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 110. United States Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 111. United States Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. United States Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 113. United States Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Canada Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 115. Canada Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 116. Canada Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 117. Canada Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 118. Canada Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. Mexico Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 120. Mexico Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 121. Mexico Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. Mexico Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 123. Mexico Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. Brazil Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 125. Brazil Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 126. Brazil Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 127. Brazil Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 128. Brazil Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. United Kingdom Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 130. United Kingdom Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 131. United Kingdom Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. United Kingdom Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 133. United Kingdom Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. Germany Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 135. Germany Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 136. Germany Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. Germany Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 138. Germany Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. France Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 140. France Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 141. France Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. France Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 143. France Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 144. Russia Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 145. Russia Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 146. Russia Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. Russia Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 148. Russia Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. Italy Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 150. Italy Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 151. Italy Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. Italy Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 153. Italy Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Spain Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 155. Spain Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 156. Spain Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 157. Spain Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 158. Spain Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. China Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 160. China Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 161. China Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 162. China Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 163. China Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. India Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 165. India Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 166. India Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. India Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 168. India Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Japan Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 170. Japan Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 171. Japan Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. Japan Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 173. Japan Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Australia Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 175. Australia Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 176. Australia Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. Australia Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 178. Australia Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. South Korea Gemcitabine Hydrochloride Market Size, 2017-2032 (USD Million)
TABLE 180. South Korea Gemcitabine Hydrochloride Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 181. South Korea Gemcitabine Hydrochloride Market Size, by Indication, 2017-2032 (USD Million)
TABLE 182. South Korea Gemcitabine Hydrochloride Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 183. South Korea Gemcitabine Hydrochloride Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. Global Gemcitabine Hydrochloride Market Share, by Key Player, 2025
TABLE 185. Global Gemcitabine Hydrochloride Market, Key Experts

Companies Mentioned

  • Accord Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Bharat Serums and Vaccines Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sagent Pharmaceuticals, Inc.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wockhardt Limited
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Gemcitabine Hydrochloride API Market - Global Forecast 2025-2030 - Product Image

Gemcitabine Hydrochloride API Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Gemcitabine Hydrochloride - Global Strategic Business Report - Product Image

Gemcitabine Hydrochloride - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Gemcitabine Hydrochloride Market Report 2026 - Product Image

Gemcitabine Hydrochloride Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Gemcitabine Hydrochloride Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type (Injection, Ready-to-use IV Solution), Indication, Patient Age Group - Product Image

Gemcitabine Hydrochloride Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type (Injection, Ready-to-use IV Solution), Indication, Patient Age Group

  • Report
  • 160 Pages
  • Global
From
Gemcitabine Hydrochloride Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Gemcitabine Hydrochloride Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.